NEWS ROOM
- 2022.08.25Notice concerning Discussions between Meiji Seika Pharma and Arcalis, Regarding the Production and Supply of “ARCT-154” for Replicon Vaccine for COVID-19 Press Release
- 2022.07.20ARCALIS and Axcelead DDP Announce Collaboration to Provide Integrated Drug Discovery Support Service for mRNA Therapeutics Press Release
- 2022.06.29Notice of Transition to a Company with an Audit and Supervisory Committee and Appointment of the Members of the Board of Directors Press Release
- 2022.02.01Axcelead Begins Joint Research with Tokyo Medical and Dental University on mRNA Drug Development for Acute Cerebral Infarction and Postresuscitation Encephalopathy Press Release
- 2022.01.12IP Generator, Axcelead, and Axcelead Drug Discovery Partners Signed a Comprehensive Business Alliance Agreement Press Release